MLR Maelor

RNS Number:4238Y
Maelor PLC
15 February 2006

                                                                15 February 2006



                                   Maelor plc



The Directors of Maelor note the recent rise in the Company's share price and
are not aware of any specific external events that may have caused the rise.



During the week, the Company achieved the return in-house of Volplex, Maelor's
treatment for hypovolaemia, enabling the Company to focus directly on increasing
sales and market share. Despite the de-stocking process involved in returning
Volplex from a distributor, Company turnover for the second half of the year is
anticipated to be in line with the levels seen in the first six months.
Operating losses are likely to half in the final six months of the year relative
to the first six months, ahead of expectations.



The Directors are pleased with the progress of the recently announced strategic
review, which they expect to complete on schedule and be in a position to update
the market in parallel with year end results.





Further information:



Tim Wright, CEO Maelor plc

01978 810 153



Ben Atwell, Financial Dynamics

020 7831 3113






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

SPMEAPALFESKEFE

Maelor (LSE:MLR)
Historical Stock Chart
From Jun 2024 to Jul 2024

Maelor (LSE:MLR)
Historical Stock Chart
From Jul 2023 to Jul 2024